Assessing the Antiangiogenic Effects of Chalcones and Their Derivatives

References

• J. Chen, C. F. Liu, and G. W. Rao, “Progress in the Synthesis, Angiogenesis Activity and Mechanism of Chalcone Derivatives,” Mini-Reviews in Organic Chemistry 17 (2020): 814–27. doi:10.2174/1570193X17666191223161941
   Web of Science ®Google Scholar
• D. Hanahan, and J. Folkman, “Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis,” Cell 86, no. 3 (1996): 353–64. doi:10.1016/S0092-8674(00)80108-7
   PubMed Web of Science ®Google Scholar
• F. Fan, A. Schimming, D. Jaeger, and K. Podar, “Targeting the Tumor Microenvironment: focus on Angiogenesis,” Journal of Oncology 2012 (2012): 281261. doi:10.1155/2012/281261
   PubMedGoogle Scholar
• Sofie Frandsen, Sascha Kopp, Markus Wehland, Jessica Pietsch, Manfred Infanger, and Daniela Grimm, “Latest Results for Anti-Angiogenic Drugs in Cancer Treatment,” Current Pharmaceutical Design 22, no. 39 (2016): 5927–42. doi:10.2174/1381612822666160715130419
   PubMed Web of Science ®Google Scholar
• G. G. Yue, B. C. Chan, H. F. Kwok, Y. L. Wong, H. W. Leung, C. J. Ji, K. P. Fung, P. C. Leung, N. H. Tan, and C. B. S. Lau, “Anti-Angiogenesis and Immunomodulatory Activities of an Anti-Tumor Sesquiterpene Bigelovin Isolated from Inula Helianthus-Aquatica,” European Journal of Medicinal Chemistry 59 (2013): 243–52. doi:10.1016/j.ejmech.2012.11.029
   PubMed Web of Science ®Google Scholar
• W. Chen, G. Zhang, L. Guo, W. Fan, Q. Ma, X. Zhang, R. Du, and R. Cao, “Synthesis and Biological Evaluation of Novel Alkyl Diamine Linked Bivalent β-Carbolines as Angiogenesis Inhibitors,” European Journal of Medicinal Chemistry 124 (2016): 249–61. doi:10.1016/j.ejmech.2016.08.050
   PubMed Web of Science ®Google Scholar
• A. Markowska, S. Sajdak, J. Markowska, and A. Huczyński, “Angiogenesis and Cancer Stem Cells: New Perspectives on Therapy of Ovarian Cancer,” European Journal of Medicinal Chemistry 142 (2017): 87–94. doi:10.1016/j.ejmech.2017.06.030
   PubMed Web of Science ®Google Scholar
• C. Wang, L. Li, D. Fu, T. Qin, Y. Ran, F. Xu, X. Du, H. Gao, S. Sun, T. Yang, et al, “Discovery of Chalcone-Modified Estradiol Analogs as Antitumour Agents That Inhibit Tumour Angiogenesis and Epithelial to Mesenchymal Transition,” European Journal of Medicinal Chemistry 176 (2019): 135–48. doi:10.1016/j.ejmech.2019.04.071
   PubMed Web of Science ®Google Scholar
• L. Mirossay, L. Varinská, and J. Mojžiš, “Antiangiogenic Effect of Flavonoids and Chalcones: An Update,” International Journal of Molecular Sciences 19 (2018): 27. doi:10.3390/ijms19010027
   Web of Science ®Google Scholar
• E. Nuti, B. Bassani, C. Camodeca, L. Rosalia, A. Cantelmo, C. Gallo, D. Baci, A. Bruno, E. Orlandini, S. Nencetti, et al, “Synthesis and Antiangiogenic Activity Study of New Hop Chalcone Xanthohumol Analogues,” European Journal of Medicinal Chemistry 138 (2017): 890–9. doi:10.1016/j.ejmech.2017.07.024
   PubMed Web of Science ®Google Scholar
• S. R. Lemes, L. A. Júnior, D. da Silva Manoel, M. A. M. de Sousa, R. D. Fonseca, R. S. Lima, C. Noda-Perez, P. R. de Melo Reis, C. G. Cardoso, E. de Paula Silveira-Lacerda, et al, “Optical Properties and Antiangiogenic Activity of a Chalcone Derivate, Spectrochim,” Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy 204 (2018): 685–95. doi:10.1016/j.saa.2018.06.099
   PubMed Web of Science ®Google Scholar
• V. Kumar, S. Kumar, M. Hassan, H. Wu, R. K. Thimmulappa, A. Kumar, S. K. Sharma, V. S. Parmar, S. Biswal, and S. V. Malhotra, “Novel Chalcone Derivatives as Potent Nrf2 Activators in Mice and Human Lung Epithelial Cells,” Journal of Medicinal Chemistry 54, no. 12 (2011): 4147–59. doi:10.1021/jm2002348
   PubMed Web of Science ®Google Scholar
• Z. Rozmer, T. Berki, and P. Perjési, “Different Effects of Two Cyclic Chalcone Analogues on Cell Cycle of Jurkat T Cells,” Toxicology In Vitro 20, no. 8 (2006): 1354–62. doi:10.1016/j.tiv.2006.05.006
   PubMed Web of Science ®Google Scholar
• T. Akihisa, H. Tokuda, D. Hasegawa, M. Ukiya, Y. Kimura, F. Enjo, T. Suzuki, and H. Nishino, “Chalcones and Other Compounds from the Exudates of Angelica k Eiskei and Their Cancer Chemopreventive Effects,” Journal of Natural Products 69, no. 1 (2006): 38–42. doi:10.1021/np058080d
   PubMed Web of Science ®Google Scholar
• J. S. Lee, Y. Kang, J. T. Kim, D. Thapa, E. S. Lee, and J. A. Kim, “The Anti-Angiogenic and Anti-Tumor Activity of Synthetic Phenylpropenone Derivatives is Mediated through the Inhibition of Receptor Tyrosine Kinases,” European Journal of Pharmacology 677, no. 1-3 (2012): 22–30. doi:10.1016/j.ejphar.2011.12.012
   PubMed Web of Science ®Google Scholar
• D. K. Mahapatra, S. K. Bharti, and V. Asati, “Anti-Cancer Chalcones: Structural and Molecular Target Perspectives,” European Journal of Medicinal Chemistry 98 (2015): 69–114. doi:10.1016/j.ejmech.2015.05.004
   PubMed Web of Science ®Google Scholar
• S. Burmaoglu, O. Algul, D. A. Anıl, A. Gobek, G. G. Duran, R. H. Ersan, and N. Duran, “Synthesis and Anti-Proliferative Activity of Fluoro-Substituted Chalcones,” Bioorganic & Medicinal Chemistry Letters 26, no. 13 (2016): 3172–6. doi:10.1016/j.bmcl.2016.04.096
   PubMed Web of Science ®Google Scholar
• S. Burmaoglu, D. Aktas Anil, A. Gobek, D. Kilic, D. Yetkin, N. Duran, and O. Algul, “Design, Synthesis and Antiproliferative Activity Evaluation of Fluorine-Containing Chalcone Derivatives,” Journal of Biomolecular Structure & Dynamics 40, no. 8 (2022): 3525–50. doi:10.1080/07391102.2020.1848627
   PubMed Web of Science ®Google Scholar
• S. Burmaoglu, A. O. Yilmaz, M. F. Polat, R. Kaya, İ. Gulcin, and O. Algul, “Synthesis of Novel Tris-Chalcones and Determination of Their Inhibition Profiles against Some Metabolic Enzymes,” Archives of Physiology and Biochemistry 127, no. 2 (2021): 153–61. doi:10.1080/13813455.2019.1623265
   PubMed Web of Science ®Google Scholar
• S. Burmaoglu, S. Ozcan, S. Balcioglu, M. Gencel, S. A. A. Noma, S. Essiz, B. Ates, and O. Algul, “Synthesis, Biological Evaluation and Molecular Docking Studies of Bis-Chalcone Derivatives as Xanthine Oxidase Inhibitors and Anticancer Agents,” Bioorganic Chemistry 91 (2019): 103149. doi:10.1016/j.bioorg.2019.103149
   PubMed Web of Science ®Google Scholar
• S. Burmaoglu, E. A. Kazancioglu, R. Kaya, M. Kazancioglu, M. Karaman, O. Algul, and I. Gulcin, “Synthesis of Novel Organohalogen Chalcone Derivatives and Screening of Their Molecular Docking Study and Some Enzymes Inhibition Effects,” Journal of Molecular Structure. 1208 (2020): 127868. doi:10.1016/j.molstruc.2020.127868
   Web of Science ®Google Scholar
• A. J. McGahon, S. J. Martin, R. P. Bissonnette, A. Mahboubi, Y. Shi, R. J. Mogil, W. K. Nishioka, and D. R. Green, “The End of the (Cell) Line: Methods for the Study of Apoptosis In Vitro,” Methods Cell Biol 46 (1995): 153–85. doi:10.1016/S0091-679X(08)61929-9
   PubMed Web of Science ®Google Scholar
• A. Güner, A. Nalbantsoy, A. Sukatar, and N. Ü. K. Yavaşoğlu, “Apoptosis-Inducing Activities of Halopteris scoparia L. Sauvageau (Brown Algae) on Cancer Cells and Its Biosafety and Antioxidant Properties,” Cytotechnology 71, no. 3 (2019): 687–704. doi:10.1007/s10616-019-00314-5
   PubMed Web of Science ®Google Scholar
• K. J. Livak, and T. D. Schmittgen, “Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2(-Delta Delta C(T)) Method,” Methods (San Diego, Calif.) 25, no. 4 (2001): 402–8. doi:10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar
• O. Algul, R. H. Ersan, M. A. Alagoz, N. Duran, and S. Burmaoglu, “An Efficient Synthesis of Novel di-Heterocyclic Benzazole Derivatives and Evaluation of Their Antiproliferative Activities,” Journal of Biomolecular Structure & Dynamics 39, no. 18 (2021): 6926–38. doi:10.1080/07391102.2020.1803966
   PubMed Web of Science ®Google Scholar
• M. A. Alagoz, “New Molecule Design with In-Silico Methods for Covid-19 Treatment,” Bioorganic and Medicinal Chemistry Reports 3 (2020): 32–40.
   Google Scholar
• A. Temirak, Y. M. Shaker, F. A. Ragab, M. M. Ali, S. M. Soliman, J. Mortier, G. Wolber, H. I. Ali, and H. I. El Diwani, “Synthesis, Biological Evaluation, and Docking Studies of New 2‐Furylbenzimidazoles as anti‐Angiogenic Agents: Part II,” Archiv Der Pharmazie 347, no. 4 (2014): 291–304. doi:10.1002/ardp.201300356
   PubMed Web of Science ®Google Scholar
• R. H. Ersan, M. A. Alagoz, A. Dogen, N. Duran, S. Burmaoglu, and O. Algul, “Bisbenzoxazole Derivatives: Design, Synthesis, In Vitro Antimicrobial, Antiproliferative Activity, and Molecular Docking Studies,” Polycyclic Aromatic Compounds 42, no. 6 (2020): 3103-3123. doi:10.1080/10406638.2020.1852589
   Web of Science ®Google Scholar
• T. Mosmann, “Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays,” Journal of Immunological Methods 65, no. 1–2 (1983): 55–63. doi:10.1016/0022-1759(83)90303-4
   PubMed Web of Science ®Google Scholar
• X. Jiang, J. Wang, X. Deng, F. Xiong, S. Zhang, Z. Gong, X. Li, K. Cao, H. Deng, Y. He, et al, “The Role of Microenvironment in Tumor Angiogenesis,” Journal of Experimental & Clinical Cancer Research 39, no. 1 (2020): 204. doi:10.1186/s13046-020-01709-5
   PubMed Web of Science ®Google Scholar
• R. Lugano, M. Ramachandran, and A. Dimberg, “Tumor Angiogenesis: Causes, Consequences, Challenges and Opportunities, Cell,” Cellular and Molecular Life Sciences : CMLS 77, no. 9 (2020): 1745–70. doi:10.1007/s00018-019-03351-7
   PubMed Web of Science ®Google Scholar
• C. Aslan, S. Maralbashi, F. Salari, H. Kahroba, F. Sigaroodi, T. Kazemi, and P. Kharaziha, “Tumor‐Derived Exosomes: Implication in Angiogenesis and Antiangiogenesis Cancer Therapy,” Journal of Cellular Physiology 234, no. 10 (2019): 16885–903. doi:10.1002/jcp.28374
   PubMed Web of Science ®Google Scholar
• A. Uccelli, T. Wolff, P. Valente, N. Di Maggio, M. Pellegrino, L. Gürke, B. Andrea, and G. B. Roberto, “Vascular Endothelial Growth Factor Biology for Regenerative Angiogenesis, Swiss,” Swiss Medical Weekly 149 (2019): w20011. doi:10.4414/smw.2019.20011
   PubMed Web of Science ®Google Scholar
• Velma Ganga Reddy, T. Srinivasa Reddy, Chetna Jadala, M. Soumya Reddy, Faria Sultana, Ravikumar Akunuri, Suresh K. Bhargava, Donald Wlodkowic, P. Srihari, and Ahmed Kamal, “Pyrazolo-Benzothiazole Hybrids: Synthesis, Anticancer Properties and Evaluation of Antiangiogenic Activity Using In Vitro VEGFR-2 Kinase and In Vivo Transgenic Zebrafish Model,” European Journal of Medicinal Chemistry 182 (2019): 111609. doi:10.1016/j.ejmech.2019.111609
   PubMed Web of Science ®Google Scholar
• N. M. Elsayed, R. A. Serya, M. F. Tolba, M. Ahmed, K. Barakat, D. A. Abou El Ella, and K. A. Abouzid, “Design, Synthesis, Biological Evaluation and Dynamics Simulation of Indazole Derivatives with Antiangiogenic and Antiproliferative Anticancer Activity, Bioorg,” Bioorganic Chemistry 82 (2019): 340–59. doi:10.1016/j.bioorg.2018.10.071
   PubMed Web of Science ®Google Scholar
• S. Salerno, E. Barresi, A. N. García-Argáez, S. Taliani, F. Simorini, G. Amendola, S. Tomassi, S. Cosconati, E. Novellino, F. Da Settimo, et al, “Discovery of Pyrido[3,2:5,6]Thiopyrano[4,3-d]pyrimidine-Based Antiproliferative Multikinase Inhibitors,” ACS Medicinal Chemistry Letters 10, no. 4 (2019): 457–62. doi:10.1021/acsmedchemlett.8b00499
   PubMed Web of Science ®Google Scholar
• K. L. Blackwell, Z. A. Haroon, S. Shan, W. Saito, G. Broadwater, C. S. Greenberg, and M. W. Dewhirst, “Tamoxifen Inhibits Angiogenesis in Estrogen Receptor-Negative Animal Models,” Clinical Cancer Research 6 (2000): 4359–64.
   Google Scholar
• D. I. Batovska, and I. T. Todorova, “Trends in Utilization of the Pharmacological Potential of Chalcones,” Current Clinical Pharmacology 5, no. 1 (2010): 1–29. doi:10.2174/157488410790410579
   PubMedGoogle Scholar
• M. Pilatova, L. Varinska, P. Perjesi, M. Sarissky, L. Mirossay, P. Solar, A. Ostro, and J. Mojzis, “In Vitro Antiproliferative and Antiangiogenic Effects of Synthetic Chalcone Analogues,” Toxicology in Vitro : An International Journal Published in Association with BIBRA 24, no. 5 (2010): 1347–55. doi:10.1016/j.tiv.2010.04.013
   PubMed Web of Science ®Google Scholar